[{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"AZD1222","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ Astrazeneca","highestDevelopmentStatusID":"9","companyTruncated":"Oxford Biomedica \/ Astrazeneca"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Vaccines Manufacturing and Innovation Centre","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AZD1222","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Vaccines Manufacturing and Innovation Centre","highestDevelopmentStatusID":"9","companyTruncated":"Oxford Biomedica \/ Vaccines Manufacturing and Innovation Centre"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"SAR422459","moa":"ABCR gene","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biomedica \/ Sanofi"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"AXO-Lenti-PD","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Axovant Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Oxford Biomedica \/ Axovant Gene Therapies"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Lentiviral vector","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Beam Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ Beam Therapeutics"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Oxford Biomedica","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Oxford Biomedica \/ AstraZeneca"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Papyrus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"PYTX-002","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Papyrus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ Papyrus Therapeutics"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AXO-Lenti-PD","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Oxford Biomedica","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biomedica \/ Oxford Biomedica"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"PhoreMost","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"LentiVector based gene therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Oxford Biomedica","highestDevelopmentStatusID":"2","companyTruncated":"Oxford Biomedica \/ Oxford Biomedica"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Oxford Biomedica \/ AstraZeneca"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Tisagenlecleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Oxford Biomedica \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Oxford Biomedica \/ Novartis"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AXO-Lenti-PD","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oxford Biomedica \/ Sio Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Oxford Biomedica \/ Sio Gene Therapies"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Recombinant ChAdOx1-S","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxford Biomedica \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Oxford Biomedica \/ AstraZeneca"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"LSA","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-T Therapy","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ LSA","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ LSA"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"OTL-203","moa":"IDUA gene","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Orchard Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ Orchard Therapeutics"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Kyverna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"KYV-101","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Biomedica \/ Kyverna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biomedica \/ Kyverna Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Oxford Biomedica

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the agreement, Kyverna gains access to LentiVector® platform, the first commercially approved lentiviral-based gene delivery system, to use with any Kyverna product, including its anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201 which specifica...

                          Brand Name : KYV-101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 20, 2023

                          Lead Product(s) : KYV-101

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Kyverna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Oxford Biomedica Solutions will provide its full platform offering to support the new partners’ pre-clinical gene therapy programmes, which cover development programmes including CNS, autoimmune disease, oncology, muscular disorder, and rare metabolic ...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 14, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The LSA grants the new partner a non-exclusive licence to utilise Oxford Biomedica’s LentiVector® platform for its application in their lead CAR-T programme, and puts in place a three-year Clinical Supply Agreement.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 26, 2022

                          Lead Product(s) : CAR-T Therapy

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : LSA

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : OTL-203, an investigational hemopoietic stem cell (HSC) gene therapy in development for the potential treatment of mucopolysaccharidosis type I Hurler’s syndrome (MPS-IH).

                          Brand Name : OTL-203

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          July 26, 2022

                          Lead Product(s) : OTL-203

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Orchard Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The manufacture of COVID-19 vaccines, Vaxzevria (Recombinant ChAdOx1-S), at Oxford Biomedica’s Oxbox facility is expected to complete in the last quarter of 2022, will be available to AstraZeneca on an as needed basis beyond 2022.

                          Brand Name : Vaxzevria

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          July 01, 2022

                          Lead Product(s) : Recombinant ChAdOx1-S

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Sio intends to return the global rights for AXO-Lenti-PD and that they intend to cease work on this gene therapy programme in Parkinson’s Disease. Sio is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD.

                          Brand Name : OXB-102

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 31, 2022

                          Lead Product(s) : AXO-Lenti-PD

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Sio Gene Therapies

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the terms of the agreement, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials with also allowing for payments for the manufacture and supply of lentiviral vectors fo...

                          Brand Name : Kymriah

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 13, 2021

                          Lead Product(s) : Tisagenlecleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Oxford Biomedica announced an 18 month supply agreement in September 2020 under a three year Master Supply and Development Agreement with AstraZeneca for large-scale manufacture of the adenovirus vector-based COVID-19 vaccine, AZD1222.

                          Brand Name : AZD1222

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 18, 2021

                          Lead Product(s) : ChAdOx1 nCoV-19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 09, 2020

                          Lead Product(s) : LentiVector based gene therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : PhoreMost

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AXO-Lenti-PD gene therapy demonstrate consistent treatment outcomes including Favorable safety and tolerability profile, with no serious adverse events attributable to gene therapy; Improvement in Hauser diary “Good ON time” and “OFF time” and ot...

                          Brand Name : OXB-102

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 29, 2020

                          Lead Product(s) : AXO-Lenti-PD

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Recipient : Sio Gene Therapies

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank